Spectral AI to Present Findings at BBA / ISBI Joint Conference
DALLAS, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), a frontrunner in artificial intelligence (AI) technology for medical diagnostics, has announced that Dr. Jeffrey Carter will present crucial findings from an extensive multicenter study. This research focuses on the use of Spectral AI’s innovative DeepView™ System, which utilizes non-invasive multispectral imaging and proprietary AI algorithms to identify non-healing areas in thermal (burn) injuries.
Dr. Carter is the Medical Director of the Burn Center at a leading university medical facility and holds a professorship in Surgery at a respected health institution. He also serves as the Chief Medical Consultant for Spectral AI.
Dr. Carter emphasizes the limited resources available for burn treatment in the U.S., noting that there are only about 130 burn centers, which results in a shortage of beds and a decline in the training of burn surgeons. In emergency situations, these constraints could lead to misdiagnoses and a lower standard of care for patients.
Importantly, the DeepView™ System has shown a remarkable ability to accurately assess burn depth, outperforming even seasoned clinicians. This supports the Company’s claim that integrating a high-performing, AI-driven model with clinician evaluations will significantly improve the speed and outcomes of treatment for patients with acute burn injuries.
“The structural challenges within our healthcare system for treating burn victims, combined with the complexities of these injuries, create significant hurdles for healthcare providers, patients, and medical institutions,” Dr. Carter remarked. “We believe the DeepView™ System can help bridge these gaps in care by providing timely and accurate assessments of burn wounds, surpassing the capabilities of even the most experienced burn physicians. This predictive technology has the potential to greatly benefit daily healthcare operations, especially during mass casualty events.”
Details of the Upcoming Presentation
Presenter: Jeffrey E. Carter, MD, FACS
Title: Burn Severity Assessment Using Multispectral Imaging and AI: Analysis of a Multicenter Study
Day: Wednesday, August 21
Time: 15:30-17:00 BST
Location: International Conference Centre (ICC) Hall 11B, Birmingham, UK
The Company’s ongoing U.S. Burn Pivotal Study aims to validate the AI-driven algorithm used by the DeepView™ System for assessing burn severity. This study represents the final clinical trial before the Company seeks FDA approval for the DeepView™ System in 2025.
About Spectral AI
Spectral AI, Inc., located in Dallas, is committed to transforming medical diagnostics through predictive AI, particularly in wound care management. The initial focus is on treating patients with burns and diabetic foot ulcers. The Company enhances patient care by “Seeing the Unknown” with its innovative DeepView™ System, a predictive device that provides clinicians with objective and immediate assessments of wound healing potential prior to any medical intervention. By leveraging algorithm-driven insights, the DeepView™ System aims to elevate the standard of care, leading to faster, more accurate treatment recommendations that improve patient outcomes while lowering overall healthcare costs.
Frequently Asked Questions
1. What is Spectral AI's DeepView™ System?
The DeepView™ System is an advanced predictive device that uses multispectral imaging and AI to evaluate the healing potential of wounds, especially in burn patients.
2. Who will be presenting at the upcoming conference?
Dr. Jeffrey Carter, the Medical Director of the Burn Center and Chief Medical Consultant at Spectral AI, will present findings from their multicenter study.
3. Where will the presentation take place?
The presentation is set to occur at the International Conference Centre (ICC) Hall 11B, Birmingham, UK.
4. Why is the DeepView™ System significant?
The DeepView™ System greatly improves the accuracy of burn depth assessments, allowing for quicker identification of non-healing areas compared to traditional methods, which enhances patient outcomes.
5. What are the next steps for Spectral AI regarding FDA approval?
The Company is currently conducting a pivotal study to validate its AI-driven algorithm, with plans to pursue FDA approval for the DeepView™ System in 2025.
